U.S. Semiconductors Stock News

Recent performance snapshot Cytokinetics (CYTK) has drawn investor attention after recent trading, with the stock last closing at US$80.62. Returns have been mixed in the short term and stronger over the past 3 months and year. See our latest analysis for Cytokinetics. The recent 1-day share price slip sits against a 90-day share price return of 32.84% and a 1-year total shareholder return of 120.09%, which points to momentum still building around Cytokinetics. If this kind of move has your...

Mueller Industries (MLI) is in focus after reporting second quarter 2026 earnings, with sales of US$1,427.92 million and net income of US$249.66 million, attracting fresh attention from investors. See our latest analysis for Mueller Industries. Mueller Industries' latest earnings have arrived alongside a share price of US$64.17. The 7 day share price return is 8.82% and the year to date share price return is 9.87%, while the 1 year total shareholder return is 47.58% and the 5 year total...

Columbia Sportswear (COLM) is back in focus as investors position ahead of its second quarter fiscal 2026 earnings report on July 30. The upcoming update highlights both growth efforts and ongoing distributor risks. See our latest analysis for Columbia Sportswear. Over the past year, Columbia Sportswear has combined a 13.26% year to date share price return with a 7.42% total shareholder return over 12 months, suggesting some positive momentum as investors weigh growth initiatives against...

Earlier this month, CenterPoint Energy’s board declared a regular quarterly cash dividend of US$0.2400 per share, up US$0.0100 from the April 2026 payout, payable on September 10, 2026 to shareholders of record on August 20, 2026. This latest increase, aligned with CenterPoint’s 6% targeted annual dividend per share growth rate, highlights management’s emphasis on a steadily rising income stream for shareholders. Next, we’ll examine how CenterPoint’s latest dividend increase, backed by its...

The sharp sell-off in artificial intelligence related stocks has rattled major chip firms and pulled wider tech indices lower, from Nvidia in New York to hardware giants in South Korea and Japan. For value focused investors, this kind of volatility can sometimes throw up opportunities in larger technology stocks that already screen as relatively healthy on fundamentals yet have seen recent share price pressure. This article looks at three stocks from a Value Stocks in the Technology Sector...

Cadence Design Systems stock has delivered a strong 129.9% return over the past five years, yet recent valuation checks and the current pricing signal that the shares may now lean expensive rather than offering clear value. Over the past 5 years, Cadence Design Systems has returned 129.9%, which sets a high bar for any new buyers looking for further gains from here. New partnerships around agentic AI for advanced system on chip design and deeper 2nm foundry collaboration can support growth...

MapLight Therapeutics recently reported positive topline results from its Phase 2 ZEPHYR trial, where ML-007C-MA met the primary endpoint by delivering a statistically significant and clinically meaningful reduction in schizophrenia symptoms versus placebo, alongside a generally well-tolerated safety profile. A particularly interesting finding was a robust, independent cognitive benefit in cognitively impaired participants, suggesting ML-007C-MA may affect both psychotic symptoms and...

Bank of Hawaii (BOH) has reported a solid Q2 2026 result, with revenue of US$193.3 million and EPS of US$1.48, supported by trailing twelve month revenue of US$751.2 million and EPS of US$5.42. The company’s revenue increased from US$171.2 million in Q2 2025 to US$193.3 million in Q2 2026, while EPS over the same quarters rose from US$1.07 to US$1.48, setting this latest report against a year of stronger profitability and firmer net margins. See our full analysis for Bank of Hawaii. With the...

Legal shockwaves from Johnson & Johnson’s proposed $5.5b talc settlement are rippling through the baby care and personal health space, reshaping how investors think about litigation risk, consumer trust, and competitive positioning. With up to $3b potentially paid out in the next year and no further payments scheduled before 2028, this attempt to resolve around 69,000 talc-related lawsuits could mark a turning point for Johnson & Johnson and its peers. Below, you will see 3 stocks exposed to...

Earlier in July 2026, ACADIA Pharmaceuticals announced that the FDA granted Fast Track designation to remlifanserin, its investigational 5-HT2A inverse agonist for hallucinations and delusions in Alzheimer’s disease psychosis, alongside progress updates on the seamless Phase 2/3 RADIANT program. This designation, coupled with ongoing Phase 3 enrollment, highlights how remlifanserin could meaningfully expand ACADIA’s late-stage CNS portfolio beyond its current commercial drugs. Next, we’ll...

Dime Commercial Bancshares, Inc. reported its second-quarter 2026 results with net interest income of US$115.19 million and net income of US$34.81 million, both higher than a year earlier, while also declaring a quarterly US$0.34375 dividend on its 5.50% Series A preferred stock payable on August 14, 2026. The combination of stronger core earnings and the continuation of preferred dividends highlights the bank’s capacity to support income-focused investors while reinforcing its capital...

The new content partnership between NBCUniversal’s Peacock and YouTube Premium has pushed streaming distribution into fresh territory, and investors in digital entertainment are watching closely. By folding Peacock’s full library, including NFL and NBA rights, into YouTube Premium from early 2027, the deal links one of the largest video platforms with a growing subscription service. It also points to new ways of sharing content, advertising, and revenue across platforms. This article walks...

New tariffs of 10% to 12.5% on nearly all US trade are shaking up global supply chains, and that puts a fresh spotlight on stocks with ties to domestic manufacturing and onshoring. For investors, the question is which companies might benefit from production rooted closer to home and which could face higher costs or pressure on margins as trade rules tighten. This article breaks down how the latest Section 301 tariffs could matter for your portfolio and profiles 3 stocks from our US Domestic...

Ohio Valley Banc (OVBC) has released its Q2 2026 results, with revenue of about US$14.8 million and EPS of roughly US$0.62, while trailing twelve month revenue sits at around US$62.4 million and EPS at about US$3.02, alongside net income of roughly US$14.2 million over that period. The company has seen quarterly revenue and EPS move within a relatively tight band over recent periods, from about US$16.2 million and US$0.89 in Q2 2025 to around US$14.8 million and US$0.62 in the latest quarter...

Ensign Group (ENSG) opened Q2 2026 with total revenue of US$1.4 billion and basic EPS of US$1.72, as part of a trailing twelve month profile that includes US$5.5 billion in revenue and EPS of US$6.57, alongside reported earnings growth of 17.3% over the past year. The company has seen revenue move from US$1.23 billion in Q2 2025 to US$1.44 billion in Q2 2026, with quarterly EPS rising from US$1.48 to US$1.72 over the same period. This sets up a results season in which net margin trends and...

Burke & Herbert Financial Services Corp. previously reported second-quarter 2026 results, with net interest income rising to US$93.05 million while net income fell to US$9.49 million, and the board declared a US$0.55 per share cash dividend payable on September 1, 2026. The combination of stronger net interest income but much lower earnings per share compared with a year earlier highlights pressures on overall profitability even as core lending revenue grows. Next, we’ll consider how this...

New US tariffs of 10% to 12.5% on almost all imports are reshaping the playing field for consumer stocks, putting pressure on import heavy business models while potentially opening the door for companies that make more of their goods at home. For investors, the key question is which stocks could see relatively better conditions if import costs stay elevated or volatile. This article breaks down three US consumer goods stocks from the US Import Substitute Consumer Goods Stocks screener that...

In July 2026, Capricor Therapeutics disclosed that FDA reviewers found no statistically significant benefit for its Duchenne muscular dystrophy cell therapy Deramiocel versus placebo and raised concerns about post-hoc changes to the Phase 3 HOPE-3 trial’s statistical analysis plan, ahead of an advisory committee review. At the same time, Capricor agreed a long-term, FDA-approval‑contingent lease for a 171,000‑square‑foot San Diego headquarters that ties future manufacturing expansion...

Global inflation trends, energy price swings and shifting central bank policies are pushing investors to look more closely at companies where analysts see healthy earnings growth potential and balance sheets that can cope with bumps in the road. The Healthy high growth potential screener focuses on stocks that meet both of these tests, so you are not just chasing growth at any price. In this article you will see 3 of the best stocks from this screener, giving you a focused starting list if...

Recently, Braze (NASDAQ:BRZE) reported that its customer engagement platform continues to gain traction, with billings rising an average of 32.1% over the past year and management signaling a positive sales outlook for the next 12 months. This performance, alongside evidence of efficient customer acquisition and clear product‑market fit, suggests Braze’s business model is scaling effectively in personalized, cross‑channel marketing. Next, we’ll examine how this strong billings growth and...

Citizens Community Bancorp (CZWI) just posted Q2 2026 results with total revenue of US$11.8 million and basic EPS of US$0.11, alongside trailing twelve month revenue of US$58.3 million and EPS of US$1.31. Over recent quarters the company has seen revenue move from US$14.8 million in Q2 2025 to US$15.6 million in Q4 2025 and US$15.4 million in Q1 2026, while quarterly EPS ranged between US$0.32 and US$0.44 before landing at US$0.11 in the latest period. This sets up a results season in which...

Why the IDE892 trial update matters for IDEAYA Biosciences stock IDEAYA Biosciences (IDYA) has moved IDE892 into Part 2 monotherapy expansion in its Phase 1/2 trial for MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic ductal adenocarcinoma. See our latest analysis for IDEAYA Biosciences. The IDE892 trial update lands at a time when IDEAYA Biosciences’ share price has shown firm momentum, with a 26.62% 90-day share price return and a 46.96% 1-year total...

Alamo Group stock has fallen 23.8% over the past year, and both its intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and its market multiples currently point to the shares trading at a discount to that intrinsic value. This raises a clear question about whether this weakness has gone too far. Alamo Group's share price decline of 23.8% over the last 12 months means investors are facing a recent loss, even as valuation tools now suggest the stock may be priced below its...

Q2 Earnings Highlight Lower Profitability For NVR NVR (NVR) reported second quarter 2026 results that showed net income of US$236.46 million, down from US$333.74 million a year earlier. Basic and diluted earnings per share also declined versus the prior period. See our latest analysis for NVR. NVR's share price has softened in recent months, with a 1 day share price return that declined 1.61%, a 30 day share price return that declined 7.57%, and a year to date share price return that declined...